Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | UNG | P13051 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 5/20 | 0.35 |
| ▸ | MAOB | P27338 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.33 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356038 | 0.79 | ALDH1A1 (0.42) | ALDH1A1LMNAALDH1A3ALDH3A1CYP2A6 | |
| SCHEMBL4629073 | 0.79 | CYP1A2 (0.32) | — | |
| SCHEMBL1453524 | 0.75 | ACHE (0.41) | ALDH1A1NPC1RAB9A | |
| SCHEMBL5953196 | 0.75 | KMT2A (0.41) | ALDH1A1 | |
| SCHEMBL2948578 | 0.75 | APP (0.51) | ALDH1A1NPC1RAB9A | |
| SCHEMBL2948576 | 0.75 | APP (0.51) | ALDH1A1NPC1RAB9A | |
| SCHEMBL3221521 | 0.74 | TSHR (0.45) | ALDH1A1MAOAMAOBTDP1 | |
| SCHEMBL2864353 | 0.74 | ACHE (0.38) | — | |
| SCHEMBL5953069 | 0.74 | DRD3 (0.40) | ALDH1A1DRD2DRD1DRD4DRD5 | |
| SCHEMBL17095072 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043512-A1 | EPITOPES OF ANTI-SERINE PROTEASE INHIBITOR KAZAL (SPIK) ANTIBODIES | IMCARE BIOTECH LLC | 2024-02-08 | — | — | US | disclosed |
| US-20230073246-A1 | BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-03-09 | — | — | US | disclosed |
| US-11542555-B2 | BAG3 as a target for therapy of heart failure | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220273810-A1 | ANTI-SERINE PROTEASE INHIBITOR KAZAL (SPIK) ANTIBODIES, IMMUNOCONJUGATES, AND METHODS OF USE | IMCARE BIOTECH, LLC | 2022-09-01 | — | — | US | disclosed |
| EP-4028132-A1 | EPITOPES OF ANTI-SERINE PROTEASE INHIBITOR KAZAL (SPIK) ANTIBODIES | Imcare Biotech, LLC (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3996816-A1 | ANTI-SERINE PROTEASE INHIBITOR KAZAL (SPIK) ANTIBODIES, IMMUNOCONJUGATES, AND METHODS OF USE | Imcare Biotech, LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-11236389-B2 | BAG3 as a target for therapy of heart failure | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210380671-A1 | COMPOSITIONS TARGETING THE SOLUBLE EXTRACELLULAR DOMAIN OF E-CADHERIN AND RELATED METHODS FOR CANCER THERAPY | BROUXHON SABINE (US) | 2021-12-09 | — | — | US | disclosed |
| US-20210253734-A1 | SERINE PROTEASE INHIBITOR KAZAL (SPIK) COMPOSITIONS AND METHODS | IMCARE BIOTECH, LLC | 2021-08-19 | — | — | US | disclosed |
| US-20210254159-A1 | OPTIMIZING BAG3 GENE THERAPY | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-08-19 | — | — | US | disclosed |
| US-8097238-B2 | Cell targeting conjugates | PETER MACCALLUM CANCER INSTITUTE (AU) | 2012-01-17 | — | — | US | disclosed |
| WO-2011140391-A2 | EGFR-RELATED POLYPEPTIDES AND METHODS OF USE | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20090069230-A1 | GDNF-DERIVED PEPTIDES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008100966-A1 | GDNF-DERIVED PEPTIDES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20070140970-A1 | Cell targeting conjugates | PETER MACCALLUM CANCER INSTITUTE | 2007-06-21 | — | — | US | disclosed |
| EP-1723139-A1 | CELL TARGETING CONJUGATES | PETER MacCALLUM CANCER INSTITUTE (AU) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005082894-A1 | CELL TARGETING CONJUGATES | PETER MACCALLUM CANCER INSTITUTE (AU) | 2005-09-09 | — | — | WO | disclosed |
| US-5439932-A | Anticholesterol agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5306728-A | Substituted amine derivatives having antihyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0448078-A2 | Substituted amine derivatives having anti-hyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070140970-A1 | Cell targeting conjugates | CD47, CD74, CD2 | ALDH1A1 1727/4885UNG 153/4885DRD2 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.